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Genotyping of methicillin 
resistant Staphylococcus aureus 
from the United Arab Emirates
Abiola Senok1*, Rania Nassar1,2, Handan Celiloglu1,3, Anju Nabi4, Mubarak Alfaresi5, 
Stefan Weber6, Irfan Rizvi3, Elke Müller7,8, Annett Reissig7,8, Darius Gawlik9,10, 
Stefan Monecke7,8,11 & Ralf Ehricht7,8,12
Reports from Arabian Gulf countries have demonstrated emergence of novel methicillin resistant 
Staphylococcus aureus (MRSA) strains. To address the lack of data from the United Arab Emirates 
(UAE), genetic characterisation of MRSA identified between December 2017 and August 2019 
was conducted using DNA microarray-based assays. The 625 MRSA isolates studied were grouped 
into 23 clonal complexes (CCs) and assigned to 103 strains. CC5, CC6, CC22 and CC30 represented 
54.2% (n/N = 339/625) of isolates with other common CCs being CC1, CC8, CC772, CC361, CC80, 
CC88. Emergence of CC398 MRSA, CC5-MRSA-IV Sri Lanka Clone and ST5/ST225-MRSA-II, Rhine-
Hesse EMRSA/New York-Japan Clone in our setting was detected. Variants of pandemic CC8-MRSA-
[IVa + ACME I] (PVL+) USA300 were detected and majority of CC772 strains were CC772-MRSA-V 
(PVL+), “Bengal- Bay Clone”. Novel MRSA strains identified include CC5-MRSA-V (edinA+), CC5-MRSA-
[VT + fusC], CC5-MRSA-IVa (tst1+), CC5-MRSA-[V/VT + cas + fusC + ccrA/B-1], CC8-MRSA-V/VT, CC22-
MRSA-[IV + fusC + ccrAA/(C)], CC45-MRSA-[IV + fusC + tir], CC80-MRSA-IVa, CC121-MRSA-V/VT, CC152-
MRSA-[V + fusC] (PVL+). Although several strains harboured SCC-borne fusidic acid resistance (fusC) 
(n = 181), erythromycin/clindamycin resistance (ermC) (n = 132) and gentamicin resistance (aacA-aphD) 
(n = 179) genes, none harboured vancomycin resistance genes while mupirocin resistance gene mupR 
(n = 2) and cfr gene (n = 1) were rare. An extensive MRSA repertoire including CCs previously unreported 
in the region and novel strains which probably arose locally suggest an evolving MRSA landscape.
Methicillin resistant Staphylococcus aureus (MRSA) is an important cause of nosocomial infections worldwide 
and is associated with significant patient morbidity, mortality and healthcare costs. The epidemiology of MRSA 
has been dynamic and with an evolution towards increasing predominance of community associated MRSA 
lineages (CA-MRSA) as agents of hospital acquired MRSA (HA-MRSA)  infections1,2. In recent years, emerging 
data on the molecular characterisation of S. aureus isolates in the hospital and community setting in countries 
of the Arabian Gulf region has contributed to changing our understanding of the diversity of isolates  present3–9. 
In accordance with reports from other parts of the world, community associated MRSA (CA-MRSA) lineages 
have overtaken HA-MRSA lineages as aetiological agents also of nosocomial infections. Interestingly, MRSA 
isolates circulating in the region represent a wide clonal  diversity3,8,10–12. Furthermore, emergence of novel and 
variant MRSA strains including those with novel SCCmec elements or with complex elements that include mecA 
as well as a gene associated with fusidic acid resistance (fusC) continue to be  reported3,8,10.
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Although MRSA contributes to the burden of S. aureus infections in the United Arab Emirates (UAE), there 
remains a paucity of data on the molecular characterization of circulating strains. The UAE is a global tourist 
hub and home to a large expatriate population including those from regions from where there are hardly any 
data on MRSA prevalence and population structure. With this dynamic population, it is plausible that a diversity 
of MRSA clones can be found that includes highly transmissible pandemic clones as well as local strains from 
different regions from which tourists and expatriates might come to the UAE. Therefore, this study was carried 
out to determine the genotypes of MRSA isolates in the UAE and to differentiate closely related strains using a 
high-resolution typing method.
Results
CC diversity, virulence and antibiotic resistance genes. A total of 625 isolates obtained from wound/
pus swabs (n = 459), blood cultures (n = 95), respiratory sites (endotracheal aspirates/sputum) (n = 50) and urine 
(n = 21) were included in the study. Based on DNA microarray analysis, these 625 MRSA isolates were grouped 
into 23 clonal complexes (CCs) which were assigned to 102 strains (Table 1) with “strains” being defined based on 
their CC affiliation, toxin gene carriage and SCCmec type (see Supplementary Table S1 online for details of strain 
assignment). The CCs were identified across study sites and there was no clustering observed of any specific CC 
based on study site or type of clinical specimen. Four predominant CCs accounted for 54.2% (n/N = 339/625) of 
isolates. These were CC30 (n = 91; 14.6%), CC5 (n = 89; 14.2%), CC22 (n = 82; 13.1%) and CC6 (n = 77; 12.3%) 
(Table 1). Other commonly identified CCs were CC1 (n = 48), CC8 (n = 40), CC772 (n = 36), CC361 (n = 35), 
CC80 (n = 27) and CC88 (n = 19). A majority of the strains belonged to CA-MRSA lineages harbouring SCC-
mec types IV and V (n/N = 610/625; 97.6%), (Supplementary Table S1 online). There was concordance between 
MRSA phenotypic and genotypic identification (data not shown).
We detected isolates harbouring SCC-borne fusidic acid resistance (fusC) gene (n = 181), erythromycin/
clindamycin resistance (ermC) gene (n = 132), and bifunctional enzyme gentamicin resistance (aacA-aphD) 
(n = 179). In addition, 25 isolates carried the fusidic acid resistance gene fusB (also known as far1). Carriage 
of the mupirocin resistance gene mupR (n = 2) and 23S rRNA methyltransferase cfr gene (n = 1) was rare while 
none of our strains carried vancomycin / teicoplanin resistance genes (vanA, vanB, vanZ). The Panton Valentine 
leukocidin (pvl) genes were present in 49% of all isolates studied while 13.8% were positive for the toxic shock 
syndrome (tst-1) gene. The prevalence rates of the antibiotic resistance and virulence genes are shown in Tables 2 
and Table 3 respectively.
Emerging clonal complexes. Our findings document the first identification of CC398 MRSA in the Ara-
bian Gulf region. The detection of pvl genes and SCCmec typing using a second array revealed it to belong to the 
Asian, human adapted lineage rather than to the European livestock-associated one. Among CC5, we report the 
Table 1.  Clonal complex and strain assignments.
Clonal complex (CC) (# of isolates in CC) Number of strain assignments
CC1 (n = 48) 7
CC5 (n = 89) 19
CC6 (n = 77) 3
CC8 (n = 40) 12
CC8/ST72 (n = 7) 2
CC9 (n = 1) 1
CC15 (n = 8) 1
CC22 (n = 82) 7
CC30 (n = 91) 6
CC45 (n = 3) 3
CC59 (n = 5) 2
CC80 (n = 27) 4
CC88 (n = 19) 6
CC96 (n = 1) 1
CC97 (n = 22) 4
CC121 (n = 8) 3
CC152 (n = 7) 3
CC239 (n = 11) 4
CC361 (n = 35) 5
CC398 (n = 3) 2
CC772 (n = 36) 4
CC1153 (n = 4) 2
CC2250 S. argenteus (n = 1) 1
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emergence of CC5-MRSA-IV Sri Lanka Clone and a second identification of ST5/ST225-MRSA-II, Rhine-Hesse 
EMRSA/New York-Japan Clone in the region (Supplementary Table S1 online). The CC5-MRSA-IV, Sri Lanka 
Clone is a CC5-MRSA carrying a SCCmec IVc element and pvl genes as well as, variably, the enterotoxin genes 
sed, sej and ser. In CC8, different variants of the pandemic CC8-MRSA-[IVa + ACME I] (PVL+) USA300 strain 
were detected including one that lost arc genes and speG while retaining opp and copA2-SCC (copper resistance), 
Table 2.  Detection of antibiotic resistance gene.
Antibiotic resistance genes # Positive (N = 625) % positive
Alternate penicillin binding protein 2, defining MRSA mecA 625 100.0
Mercury resistance operon merA; merB 0 0.0
SCCmec XI mecC; blaZ-SCCmec XI 0 0.0
Beta-lactamase operon blaZ ; blaI; blaR 588 94.1
rRNA adenine N-6-methyl-transferase, erythromycin/clindamycin resist-
ance ermA 15 2.4
Erythromycin/clindamycin resistance ermB 4 0.6
Erythromycin/clindamycin resistance ermC 132 21.1
Lincosamide Nucleotidyltransferase linA 10 1.6
Energy-dependent efflux of erythromycin msrA 101 16.2
Acetyl-transferase inactivating streptogramin A vatB 0 0.0
ATP binding protein, Streptogramin A resistance vgaA 0 0.0
Bifunctional enzyme gentamicin resistance aacA-aphD 179 28.6
Amino-glycoside adenyl-transferase, tobramycin resistance aadD 47 7.5
3′5′-Aminoglycoside phosphotransferase, neo-/kanamycin resistance aphA3 138 22.1
Streptothricin acetyltransferase sat 129 20.6
Dihydrofolate reductase type 1 dfrA 87 13.9
Fusidic acid resistance fusB 25 4.0
Hypothetical protein associated with fusidic acid resistance Q6GD50 (fusC) 181 29.0
Mupirocin resistance protein mupR 2 0.3
Tetracycline resistance tetK 85 13.6
Tetracycline resistance tetM 18 2.9
Chloramphenicol acetyltransferase cat 5 0.8
23S rRNA methyltransferase cfr 1 0.2
Chloramphenicol/florfenicol exporter fexA 10 1.6
Metallothiol transferase
fosB 403 64.5
fosB-plasmid 0 0.0
Quaternary ammonium compound resistance protein A/B qacA; qacC 6 1.0
Transport-/efflux protein tetEfflux 539 86.2
Vancomycin resistance genes vanA; vanB 0 0.0
Teicoplanin resistance gene from enterococci vanZ 0 0.0
Table 3.  Detection of virulence genes.
Virulence genes # Positive (N = 625) % positive
Toxic shock syndrome toxin 1 tst1 86 13.8
Panton Valentine leukocidin F/S component lukF-PV; lukS-PV 306 49.0
Staphylokinase sak 557 89.1
Chemotaxis-inhibiting protein chp 272 43.5
Staphylococcal. Complement inhibitor scn 597 95.5
Exfoliative toxin serotype A etA 3 0.5
Exfoliative toxin serotype B etB 1 0.2
Exfoliative toxin D etD 27 4.3
Epidermal cell differentiation inhibitor A edinA 9 1.4
Epidermal cell differentiation inhibitor B edinB 32 5.1
Epidermal cell differentiation inhibitor C edinC 1 0.2
Arginine catabolic mobile element locus ACME 17 2.7
Staphylococcus aureus surface protein G sasG 512 81.9
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as well as putative PVL-deletion mutants (Supplementary Table S1 online). For the first time in our region, we 
report identification of the ACME-negative/PVL-positive CC8-MRSA-[SCCmec IVc + Hg], which is a strain fre-
quently described from Spain and Latin America (Supplementary Table S1 online). Another emerging strain was 
CC22-MRSA-IV harbouring pvl and tst1 genes. A majority of the CC772 MRSA was assigned to CC772-MRSA-
V (PVL+), "Bengal Bay Clone" while some of the CC772 isolates presented with other, unusual SCCmec variants.
Novel variant MRSA strains. We identified novel variant MRSA strains from 9 CCs, namely:
CC5  Four novel variant strains were identified, three of which carried SCCmec type V. All the strains carried 
regulatory and capsular genes agrII and cap5 respectively. Although all harboured the egc cluster enter-
otoxin genes, the edinA and tst-1 genes were found in single strains respectively. The CC5-MRSA-IVa 
(tst1+) was the only one with SCCmec type IV and it uniquely harboured SCCmec IVa instead of usual 
IVc. Both CC5-MRSA-[VT + fusC] and CC5-MRSA-[V/VT + cas + fusC + ccrA/B-1] carried the fusC 
gene. The CC5-MRSA-[VT + fusC] with SCCmec VT + fusC was identified as an unknown CC5/72 
strain. A novel SCCmec element was exhibited by CC5-MRSA-[V/VT + cas + fusC + ccrA/B-1] which 
also carried the highest repertoire of antibiotic resistance genes among the novel strains (Table 3).
CC8  The novel variant strain in this CC was the CC8-MRSA-V/VT which uniquely harboured a SCCmec 
V sub-type (as in WIS; GenBank AB121219.1) and harboured the cassette chromosome recombinase 
genes ccrC on the SCCmec element. No toxin associated genes were identified in this strain.
CC22  The CC22-MRSA-[IV + fusC + ccrAA/(C)] had a new SCCmec element characterised by carriage of 
SCCmec type IV with ccrAA/C recombinase genes and fusC gene. In addition to egc cluster which is 
usually found in CC22 MRSA, this strain also harboured tst1 gene.
CC45  The CC45-MRSA-[IV + fusC + tir] harboured the combination of fusC and tirS genes on the SCCmec 
element making is a novel CC45 variant strain.
CC80  CC80-MRSA nearly always harbour PVL and SCCmec IVc while lacking enterotoxin genes. However, 
this novel variant had SCCmec IVa, harboured enterotoxin genes (seb, sek, seq) and was negative for 
pvl genes.
CC121  Subtyping of the CC121 strains revealed the presence of a variant CC121-MRSA- VT strain with the 
SCCmec VT (GR1).
CC152  The CC152-MRSA-[V + fusC] (PVL+) is the only novel variant strain harbouring the pvl genes. The 
carriage of SCC [mec V + fusC] is novel in this CC.
CC361  One CC361 strain uniquely carried an SCCmec V / cas composite element. It also harboured tst1 gene 
and a complement of enterotoxin genes (sec, sel, egc cluster).
CC1153  Two PVL-positive CC1153-MRSA isolates were observed that presented with a mec complex B, ccrA/
B1 recombinase genes and the fusC gene. Table 4 shows the genetic characterization of the novel 
strains.
Discussion
In recent years, emerging data globally and specifically in the Arabian Gulf region, have shown an evolving MRSA 
epidemiology with a shift to predominance of CA-MRSA lineages in nosocomial infections and an emergence 
of novel strains leading to an increased biological diversity of MRSA strains as well as to a greater diversity of 
SCCmec elements and variants thereof. In the UAE, MRSA contributes to the burden of infection and 30% of 
MRSA isolates identified at a tertiary care facility between 2011 and 2012 were CA-MRSA  lineages13. Indeed, 
Sonnevend et al. also reported a trend of increasing CA-MRSA lineages between 2003 and 2008 at another 
tertiary care facility in the  UAE14. However, data on the molecular characterization and strain assignments of 
circulating MRSA in the UAE are lacking. With the rapidly evolving changes reported in neighbouring countries 
and the dynamic population of the UAE, this study provides a much-needed snapshot of the genetic make-up 
of MRSA strains circulating in the UAE. Our findings demonstrate that an extensive MRSA repertoire of pre-
dominantly CA-MRSA lineage including CCs previously unreported in the region, plus rare and novel strains are 
present in the UAE. While the predominance of CC5, CC6, CC22 and CC30 is in accordance with reports from 
other countries in the region, identification of several pandemic MRSA strains and their variants such as CC8-
MRSA-[IVa + ACME I] (PVL+), USA300, CC22-MRSA-IV UK-EMRSA-15/Barnim EMRSA; CC30-MRSA-IV 
(PVL+), Southwest Pacific Clone and the HA-MRSA lineage CC239-MRSA-[mec III + Cd/Hg + ccrC] is of concern 
in light of enhanced virulence, fitness and survivability of these strains. Furthermore, the first identification of 
CC398 MRSA heralds ominously the appearance of yet another previously unreported clonal complex in our 
region. The CC398 MRSA identified is the PVL-positive human variant of MRSA CC398 which is believed to 
have originated in South East Asia and is a frequent cause of infections in China and  Vietnam15–17. In Europe, 
links to South East Asia were demonstrated in cases of infections and outbreaks associated with this CC398-
MRSA  strain15,18. It is therefore highly likely that this strain was introduced to the UAE from South East Asia or 
even possibly via Europe.
CC5-MRSA are globally  common19 with CC5-MRSA-IV (PVL + /edinA+), WA MRSA-121, CC5-MRSA-
[IV + fus + ccrAB], “Maltese Clone” and CC5-MRSA-IV (tst1+), being the prevalent strains in the Arabian Gulf 
 region3,4,6,20. Recently, the emergence of CC5-MRSA-VI strain including a novel variant which harboured the 
Staphylococcal TIR-protein binding protein gene (tirS) as additional payload on SCCmec was reported in Saudi 
Arabia 8. Identification of eight CC5-MRSA-[VI + fusC] including two with tirS in the current study suggests 
dissemination of this strain in the region. It has been postulated that the tirS gene confers enhanced bacterial 
survival and because it is located on a mobile genetic element in S. aureus, in this case an SCC element together 
with fusC, horizontal gene transfer among MRSA strains is  likely8,21. In addition to the CC5-MRSA we also 
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identified two other strains with tirS namely a novel CC45 variant, CC45-MRSA-[IV + fusC + tir], and CC1-MRSA 
[VT + fusC + tir + ccrAB1]. These findings are supportive of the notion for on-going horizontal gene transfer 
among MRSA strains in our setting.
The occurrence of antibiotic resistance and virulence genes on MRSA SCCmec/fus genetic elements is sug-
gestive of novel adaptive  mechanisms22. A high consumption of fusidic acid in the population confers a selective 
advantage for the emergence and proliferation of strains carrying the fusC  gene23. When fusC and mecA co-exist 
on the SCC element, fusidic acid use could promote MRSA in the community while beta-lactam use promotes 
fusidic acid resistance in the hospital. Hence, MRSA strains with SCCmec + SCCfus composite elements have a 
selective advantage in both the hospital and community settings. The high prevalence of MRSA strains with fusC 
gene plus presence of CC80 MRSA (which usually harbour fusB) suggests on-going community misuse of fusidic 
acid as a driving factor for MRSA evolution in our setting. Therefore, future emergence of MRSA strains with 
increased bacterial fitness, resistance and virulence is possible, hence continued surveillance for early detection 
and responsible use of antibiotics is necessary.
Recently reported phylogenetic analysis of CC5 PVL-positive MRSA from four continents showed geographi-
cal clustering with the identification of the ST5-PVL-positive MRSA-IVc Sri Lanka  clone24. Wider geographical 
spread of this clone was demonstrable with its identification in England and Australia where demonstrable 
links to Sri Lanka were not consistently  established24. Our study documents the first report of CC5-MRSA-IV 
Sri Lanka Clone with two distinct variants based on carriage or absence of enterotoxin genes (sed, sej, ser) in 
Table 4.  Characterization of novel methicillin-resistant Staphylococcus aureus strains. *Present in one isolate; 
agr accessory gene regulator; ccr cassette chromosome recombinase gene; ugpQ glycerophosphoryl diester 
phosphodi-esterase, associated with mecA; mecA alternate penicillin binding protein 2, defining MRSA; 
Q6GD50 (fusC) hypothetical protein associated with fusidic acid resistance; cap, capsule gene; blaZ beta-
lactamase; blaI beta lactamase repressor (inhibitor); blaR beta-lactamase regulatory protein; fosB Metallothiol 
transferase; tetEfflux transport-/efflux protein; tetM/K tetracycline resistance markers; ermC; rRNA adenine 
N-6-methyl-transferases causing erythromycin/clindamycin resistance; cat chloramphenicol acetyltransferase; 
fexA chloramphenicol/florfenicol exporter; aacA-aphD bifunctional enzyme gentamicin resistance; aphA3 
3′5′-aminoglycoside phosphotransferase, neo-/kanamycin resistance; sat streptothricin acetyltransferase; 
far1 fusidic acid resistance; egc cluster: enterotoxins g,i,m,n,o,u; sea enterotoxin A; seb enterotoxin B; sec 
enterotoxin C; sed enterotoxin D; sej, enterotoxin J; sek enterotoxin K; sel enterotoxin L; seq enterotoxin Q; tst1 
toxic shock syndrome toxin 1; lukF-PV/lukS-PV, Panton Valentine leukocidin F/S component; hla, haemolysin 
alpha; sak staphylokinase; scn staphylococcal complement inhibitor; chp chemotaxis-inhibiting protein 
(CHIPS); edinA  intercellular adhesion protein A/C/D; clfA/B clumping factor A/B; fnbA/B fibronectin-binding 
protein A/B.
Clonal complex Novel variants
SCC mec-complex 
associated genes
Regulatory and capsule 
genes
Antibiotic resistance 
genes
Toxin associated 
virulence genes Other virulence genes
CC5
CC5-MRSA-V (edinA+)
(n = 1)
ugpQ; mecA; ccrA-2; 
ccrB-2 agrII; cap5
blaZ; blaI; blaR; fosB; 
tetEfflux egc cluster
hla; sak; chp; scn; edinA; 
icaA/C/D; clfA/B; fnbA/B
CC5-MRSA-[VT + fusC]
(n = 2)
ugpQ; mecA; Q6GD50 
(fusC); ccrAA; ccrC agrII; cap5
blaZ; blaI; blaR; fosB; 
tetEfflux seb; egc cluster
hla; sak; scn; icaA/C/D; 
clfA/B; fnbA/B
CC5-MRSA-IVa (tst1+)
(n = 1)
ugpQ; mecA; ccrA-2; 
ccrB-2 agrII; cap5
blaZ; blaI; blaR; fosB; 
tetEfflux tst1; sea; egc cluster
hla; sak; chp; scn; 
icaA/C/D; clfA/B; fnbA/B
CC5-MRSA-[V/
VT + cas + fusC + ccrA/B-1]
(n = 1)
ugpQ; mecA; ccrA-1; 
ccrB-1; ccAA; ccrC; 
Q6GD50 (fusC); cas
agrII; cap5
blaZ; blaI; blaR; ermC; 
tetK; tetM; cat; fexA; 
fosB; tetEfflux
sea; sed; sej; ser; egc 
cluster
hla; sak; scn; icaA/C/D; 
clfA/B
CC8 CC8-MRSA-V/VT(n = 1 ugpQ; mecA; ccrC agrI; cap5
blaZ; blaI; blaR; far1; 
fosB; tetEfflux –
hla; icaA/C/D; clfA/B; 
fnbA
CC22
CC22-MRSA-
[IV + fusC + ccrAA/(C)]
(n = 1)
ugpQ; mecA; ccAA; ccrC; 
Q6GD50 (fusC) agrI; cap5 blaZ; blaI; blaR tst1; egc cluster
hla; sak; chp; scn; 
icaA/C/D; clfA/B; cna; 
fnbA/B
CC45
CC45-MRSA-
[IV + fusC + tir]
(n = 1)
ugpQ; mecA; ccrA-2; 
ccrB-2; Q6GD50 (fusC); 
tirS
agrI; cap8 tetEfflux sek; egc cluster hla; sak; chp; scn; icaA/C/D; clfA/B; fnbA
CC80 CC80-MRSA-IVa(n = 1)
ugpQ; mecA; ccrA-2; 
ccrB-2 agrIII; cap8
blaZ; blaI; blaR; ermC; 
tetEfflux seb; sek; seq;
hla; sak; chp; scn; etD; 
edinB; icaA/C/D; clfA/B; 
fnbA/B
CC121 CC121-MRSA-V/VT(n = 1)
ugpQ; mecA; ccrAA; 
ccrC; Q6GD50 (fusC) agrIV; cap8
blaZ; blaI; blaR; aacA-
aphD; fosB; tetEfflux egc cluster
hla; sak; scn; etA; etB; 
edinC; icaA/C/D; clfA/B; 
fnbA/B
CC152
CC152-MRSA-[V + fusC] 
(PVL+)
(n = 1)
ugpQ; mecA; ccrAA; 
ccrC; Q6GD50 (fusC) agrI; agrIV; cap5
blaZ; blaI; blaR; ermC; 
aacA-aphD; tetK; 
tetEfflux
lukF-PV; lukS-PV hla; sak; scn; edinB; icaA/D; clfA/B; fnbA/B
CC361
CC361-MRSA-V (SCCmec 
V/cas composite element)
(n = 2)
ugpQ; mecA; ccrAA; 
ccrC; agrI; cap8
blaZ; blaI; blaR; ermC; 
aphA3; sat; tetK; fosB; 
tetEfflux
tst1; sec; sel; egc cluster hla; sak; chp; scn; icaA/C/D; clfA/B; fnbA/B
CC1153
CC1153-MRSA with SCC-
mec I + fusC (PVL+)
(n = 2)
ugpQ; mecA; ccrA-1; 
ccrB-1; Q6GD50 (fusC) agrII; cap5
blaZ; blaI; blaR; ermC*; 
tetEfflux lukF-PV; lukS-PV
hla; sak; scn; icaA/C/D; 
clfA/B; fnbA/B
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our setting. The detection of CC5-MRSA-IV Sri Lanka Clone also underscores the need for continued surveil-
lance to keep track of introduction of new MRSA strains into the population. While it is likely that this strain 
was introduced rather than arising de novo in the UAE, we were unable to establish direct travel links with 
Sri Lanka probably because this information was sought retrospectively and patients might have acquired the 
strains through contact with healthcare workers or carriers with epidemiological links. The ST5/ST225-MRSA-
II, Rhine-Hesse EMRSA/New York-Japan Clone identified in this study is a HA-MRSA lineage pandemic strain 
which has been reported in Europe, Asia, North America and  Australia19,25. It has previously been identified in 
Kuwait and our findings demonstrate the second report in our region. Although variants of this MRSA strain 
harbouring arginine catabolic mobile element (ACME) have been reported, this was not evident in the strain 
found in this  study25. Further identification of novel strains within CC5 including edinA + variant, and strains 
with new SCCmec elements including SCC [VT + fusC] and SCC-[V/VT + cas + fusC + ccrA/B-1] are suggestive 
of ongoing genetic modification and recombination, among CC5-MRSA strains circulating in the UAE, or of 
importation from yet unidentified sources.
CC22 is a widespread clonal group which is prevalent in this region. Using high-resolution typing methods 
with SCCmec subtyping we had previously identified the regional presence of six distinct C22-MRSA-IV  strains11 
and recently an additional novel variant with SCCmec V/VT + fusC and pvl was reported from Saudi  Arabia8. 
In this study, these previously reported strains as well as the European pandemic strain CC22-MRSA-IV (UK-
EMRSA-15/Barnim EMRSA) were detected, indicative of strong links to Middle East, India and Europe for the 
evolution of CC22-MRSA in the UAE. In addition, our findings reflect on-going expansion of the diversity of 
CC22 MRSA strains with the identification of the previously undescribed CC22-MRSA-[IV + fusC + ccrAA/(C) 
which harboured a novel SCCmec element.
The CC772-MRSA-V (PVL+), Bengal Bay Clone is believed to have emerged in the Indian subcontinent from 
the same lineage as the widespread CC1 and CC5 strains 26–28. In a recent report from Pakistan, a majority of the 
characterised MRSA strains belonged to this  CC29. In Western Europe, infections with CC772-MRSA are com-
monly associated with previous travel or patient´s ethnic origin from the Indian sub-continent 26. Having been 
previously reported in Saudi Arabia, Oman and Kuwait, its identification in the UAE is not surprising giving the 
dynamic population movement with the Indian  subcontinent4,9,30.
MRSA CC121, CC152, CC361, and CC1153 are considered to be emerging in our region as variant strains 
belonging to these CCs are continually reported. It is therefore not surprising that other novel variant strains 
identified in this study belonged to these CCs 3,8. CC152-MRSA-V has been reported from Germany, Australia, 
Sweden, Switzerland, the Balkans, Saudi Arabia and  Kuwait3,8,19,31. In accordance with reported literature, the 
CC152-MRSA-V identified in this study harbour the pvl and edinB genes, and lacked enterotoxin  genes19. This 
strain carried erythromycin/clindamycin resistance ermC gene which was not present in previously described 
 strains3,8.
The first identification of CC361 in Saudi Arabia was recently reported with detection of variant strains 
similar to those previously described in Kuwait indicative of regional  spread3,8. Although CC361-MRSA had 
previously been described as a rare strain in the  UAE19, and only one CC361-MRSA-[V/VT + fusC] was found 
as nasal colonizer in a recent study from UAE dental  clinics32, the current findings suggest a wider occurrence 
of this CC. Similar to our findings, a recent report from Kuwait describing 102 novel MRSA variants identified 
32 as CC361  strains3. With up to 5% (n/N = 35/625) of our isolates belonging to CC361-MRSA inclusive of a 
novel strain with SCCmec V / cas composite element, it appears that we can no longer consider this as a rare 
MRSA lineage in our setting.
In conclusion, an extensive MRSA repertoire which includes CCs previously unreported in the region, plus 
pandemic, rare and novel variant strains are present in the UAE. Some strains detected occur in other countries, 
so a travel connection is possible. Others which have not been described elsewhere, probably evolved within the 
region. The lack of documentation of travel history for our patients is a limitation of this study as such infor-
mation would have been helpful in mapping the travel connections. However, in a population as diverse as the 
UAE, it should be noted that importation of a strain from abroad could have multiple sources and prior travel 
by the patient represents only one piece of the puzzle. An on-going, sustained transmission of at least some of 
the “imported” clones might have already started within the UAE population and affecting individuals who 
previously did not travel. Nevertheless, our findings provide the first detailed information on the genotyping of 
MRSA isolates in the UAE, providing important baseline data for future surveillance work and whole genome 
sequencing of novel strains to help understand MRSA evolution and epidemiology in the UAE.
Materials and methods
Specimen collection and bacterial strains: MRSA isolates were identified between December 2017 and August 
2019 at four diagnostic microbiology laboratories associated with secondary and tertiary care facilities, across 
three Emirates (Dubai, Abu Dhabi and Umm Al Quwain) in the UAE, with no routine inter-hospital transfer of 
patients. Apart from Abu Dhabi isolates which were obtained between December 2017 and August 2018, those 
from other Emirates were identified between December 2017 and August 2019. Only consecutive MRSA isolates 
associated with clinical infection were included with only one isolate per patient. There was no restriction on 
patient age for inclusion of isolates. However, all isolates obtained from specimens (nasal/axillary swabs) collected 
for MRSA screening were excluded. Identification of S. aureus and confirmation of methicillin resistance were 
performed using the Vitek automated platform (bioMérieux, Marcy-l’Étoile, France) in the diagnostic laboratory 
in accordance with manufacturer’s instructions and Clinical and Laboratory Standards Institute  guidelines33. 
Ethical approval was obtained from Mohammed Bin Rashid University, Dubai Scientific Research and Medi-
clinic Hospitals ethics committees (MBRU-IRB-2018–019; DSREC-05/2018_11 and CR/2018/42). As the study 
involved use of MRSA isolates already identified as part of routine diagnostic investigation, waiver of informed 
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consent was granted by the above-mentioned ethics committees. All methods in the study were carried out in 
accordance with relevant guidelines and regulations. All MRSA isolates were stored at -80 °C pending molecular 
characterisation.
Molecular characterisation of isolates was carried out using the StaphyType DNA microarray (Abbott [Alere 
Technologies GmbH], Jena, Germany). The previously described probes, primers, and procedures were used for 
the detection of species markers, virulence and resistance genes as well as for SCCmec  subtyping19,34,35. Microarray 
images were taken and analysed using the dedicated reader and software (Alere Technologies). The analysis of 
presence or absence of target gene, assignment to clonal complex, sequence type and strains as well as SCCmec 
type was carried out as previously  described19,34,35. Selected isolates were further characterised using a second 
array that facilitated assignment to SCCmec  subtypes35.
Data availability
Data generated or analysed during this study are included in this published article.
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